Drugs / Substance P-Saporin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02036281 | Jan 2014 → Sep 2016 | high grade malignant neoplasm, neurological pain disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Substance P-Saporin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02036281 ↗ |
| Known as | SP-SAP | “The subjects will be treated with a single dose of SP-SAP.” NCT02036281 ↗ |
| Route | Intrathecal | “the subject will have a catheter inserted into their spine and will receive the study drug intrathecally (into their spine)” NCT02036281 ↗ |